William Blair, Sofi and Affirm

William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...
Equities research analysts at William Blair dropped their Q4 2025 EPS estimates for Zumiez in a research report issued on ...
William Blair Small-Mid Cap Core Fund earns an Average Process Pillar rating. The predominant contributor to the rating is the fund's strong long-term risk-adjusted performance. This can be seen ...
"It is my pleasure to welcome Terence to William Blair’s Healthcare investment banking practice and its biopharma group," said Steve Tole, head of Healthcare investment banking at William Blair. "Our ...
Research analysts at William Blair boosted their FY2025 EPS estimates for shares of Exelixis in a research report issued on ...
William Blair Growth Fd earns a Below Average Process Pillar rating. The process benefits from the stability of the management team. Specifically, the fund has not seen a manager change in the ...
William Blair initiated coverage of Elevation Oncology (ELEV) with an Outperform rating without a price target The shares offer “high potential reward for a relatively low upfront investment ...
William Blair analyst Margaret Kaczor upgraded CVRx (CVRX) to Outperform from Market Perform.Stay Ahead of the Market:Discover outperforming ...
Equities researchers at William Blair lifted their FY2024 earnings estimates for Shake Shack in a research report issued to ...